FDA OKs Merck's combo therapy to reduce cholesterol, glucose levels

10/9/2011 | Reuters · WebMD

Merck secured marketing approval from the FDA for Juvisync, a treatment containing the firm's type 2 diabetes pill Januvia and cholesterol-lowering statin Zocor. The fixed-dose combination comes in multiple strengths to meet individual patient needs. "Dose selection should factor in what other drugs the patient is taking," said FDA official Dr. Mary H. Parks.

View Full Article in:

Reuters · WebMD

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA